{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:45Z","timestamp":1789140705256,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eprac.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:31:31Z","timestamp":1733196691000},"page":"188-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Qian-Qin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ya","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3284-8628","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.eprac.2024.11.013_bib1","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2024.11.013_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2024.11.013_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.013_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. In 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.013_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1123\/jpah.2020-0604","article-title":"Effects of physically active lessons on movement behaviors, cognitive, and academic performance in elementary schoolchildren: ERGUER\/Aracaju project","volume":"18","author":"Barboza","year":"2021","journal-title":"J\u00a0Phys Activ Health"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.013_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00592-020-01605-6","article-title":"Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study","volume":"58","author":"Lee","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.eprac.2024.11.013_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00125-021-05628-8","article-title":"Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial","volume":"65","author":"Thomsen","year":"2022","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.eprac.2024.11.013_bib10","first-page":"47","article-title":"The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study","volume":"9","author":"Ozeki","year":"2022","journal-title":"Medicines (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.013_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.013_bib12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.013_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eprac.2024.11.013_bib15","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.eprac.2024.11.013_bib16","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.eprac.2024.11.013_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research ed)"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.eprac.2024.11.013_bib19","series-title":"MBNMAdose: An R package for incorporating dose-response information into Network Meta-Analysis","author":"Pedder","year":"2021"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jrsm.1085","article-title":"Assessing key assumptions of network meta-analysis: a review of methods","volume":"4","author":"Donegan","year":"2013","journal-title":"Res Synth Methods"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.013_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.csda.2010.01.025","article-title":"Assessing local model adequacy in bayesian hierarchical models using the partitioned deviance information criterion","volume":"54","author":"Wheeler","year":"2010","journal-title":"Comput Stat Data Anal"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.013_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3758\/s13423-018-01563-9","article-title":"Assessing the practical differences between model selection methods in inferences about choice response time tasks","volume":"26","author":"Evans","year":"2019","journal-title":"Psychon Bull Rev"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaip.2016.04.022","article-title":"The minimally clinically important difference (MCID): what difference does it make?","volume":"4","author":"Bernstein","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.013_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12874-021-01228-7","article-title":"Using a distribution-based approach and systematic review methods to derive minimum clinically important differences","volume":"21","author":"Watt","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.013_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eprac.2024.11.013_bib27","article-title":"The effects of Exenatide once weekly (EXQW) and Exenatide twice a day (EXBID) on beta-cell function in type 2 diabetes: a systematic review and network meta-analysis","volume":"2019","author":"Wang","year":"2019","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.eprac.2024.11.013_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.013_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-022-01445-4","article-title":"HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target","volume":"21","author":"Ceriello","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.013_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.013_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabol"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.013_bib32","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.013_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1574886315999201208212356","article-title":"Efficacy and cardiovascular safety of GLP-1 receptor analogues","volume":"16","author":"Iqbal","year":"2021","journal-title":"Curr Drug Saf"},{"issue":"5","key":"10.1016\/j.eprac.2024.11.013_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/dom.12240","article-title":"Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type\u00a02 diabetes mellitus","volume":"16","author":"Torekov","year":"2014","journal-title":"Diabetes, obesity & metabolism"},{"issue":"3","key":"10.1016\/j.eprac.2024.11.013_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1079\/BJN20031064","article-title":"Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects","volume":"91","author":"N\u00e4slund","year":"2004","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2024.11.013_bib36","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/MJT.0000000000001588","article-title":"Tirzepatide: a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 agonist for the management of type 2 diabetes mellitus","volume":"30","author":"Wong","year":"2023","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.eprac.2024.11.013_bib37","article-title":"Research progress on the GIP\/GLP-1 receptor coagonist tirzepatide, a rising star in type 2 diabetes","volume":"2023","author":"Ma","year":"2023","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.eprac.2024.11.013_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metabol"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.013_bib39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2337\/dc16-0351","article-title":"Roles of the gut in glucose homeostasis","volume":"39","author":"Holst","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.013_bib40","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1210\/en.2012-2069","article-title":"A\u00a0surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery","volume":"154","author":"Kohli","year":"2013","journal-title":"Endocrinology"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T18:21:30Z","timestamp":1740594090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1530891X24008449"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.013","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}